Akebia Therapeutics, Inc. (AKBA): Price and Financial Metrics
AKBA Price/Volume Stats
| Current price | $1.37 | 52-week high | $2.48 |
| Prev. close | $1.36 | 52-week low | $0.65 |
| Day low | $1.35 | Volume | 2,108,800 |
| Day high | $1.41 | Avg. volume | 4,321,331 |
| 50-day MA | $1.59 | Dividend yield | N/A |
| 200-day MA | $1.32 | Market Cap | 286.84M |
AKBA Stock Price Chart Interactive Chart >
Akebia Therapeutics, Inc. (AKBA) Company Bio
Akebia Therapeutics focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Latest AKBA News From Around the Web
Below are the latest news stories about AKEBIA THERAPEUTICS INC that investors may wish to consider to help them evaluate AKBA as an investment opportunity.
Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceAkebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11th, 2024 at 11:15 a.m. PST. |
Akebia Therapeutics (NASDAQ:AKBA) shareholders have earned a 265% return over the last yearIt hasn't been the best quarter for Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders, since the share price has... |
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 31,000 shares of Akebia's common stock on November 30, 2023, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
Top Penny Stocks for Q4 2023Top penny stocks this month include Myomo Inc., Expion360 Inc., and Akebia Therapeutics Inc., all of which have more than tripled in value this last year. |
Akebia Therapeutics to Present at Piper Sandler Healthcare ConferenceAkebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28th at 10:30 a.m. EST. |
AKBA Price Returns
| 1-mo | -38.01% |
| 3-mo | -8.67% |
| 6-mo | 63.08% |
| 1-year | 91.77% |
| 3-year | -55.37% |
| 5-year | -78.49% |
| YTD | 10.48% |
| 2023 | 114.90% |
| 2022 | -74.47% |
| 2021 | -19.29% |
| 2020 | -55.70% |
| 2019 | 14.29% |
Continue Researching AKBA
Here are a few links from around the web to help you further your research on Akebia Therapeutics Inc's stock as an investment opportunity:Akebia Therapeutics Inc (AKBA) Stock Price | Nasdaq
Akebia Therapeutics Inc (AKBA) Stock Quote, History and News - Yahoo Finance
Akebia Therapeutics Inc (AKBA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...